DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that its CEO, Scott Plesha, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 10:00 a.m. Eastern Time. The Pelthos management team is scheduled to host one-on-one meetings with investors and attendees during the confere ...

Core Insights - Pelthos Therapeutics Inc. has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd. for $1.8 million, enhancing its portfolio of FDA-approved therapeutic products [1][2][3] Company Overview - Pelthos Therapeutics is focused on commercializing innovative therapeutic products to address unmet patient needs, with its lead product ZELSUVMI™ approved in 2024 [12] Acquisition Details - The acquisition of Xeglyze allows Pelthos to commercialize the product worldwide without any future milestone or royalty payments to Hatchtech [2][3] - Xeglyze is a novel, FDA-approved pediculicide for treating head lice in patients aged 6 months and older, with a single 10-minute application [6][8] Product Information - Xeglyze demonstrates both ovicidal and lousicidal activity, offering a more effective treatment compared to existing products that require multiple applications [5][6] - The product's active ingredient, abametapir, inhibits metalloproteinases critical to lice egg development and survival [6] Market Context - Head lice infestations are common in the U.S., affecting an estimated 6 to 12 million children aged 3 to 11 annually, indicating a significant market opportunity for Xeglyze [4]

Core Insights - Pelthos Therapeutics has launched ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum, a viral skin condition affecting approximately 16.7 million people in the U.S. with 6 million new cases annually [1][5] Company Developments - Pelthos has signed its first commercial agreement with a Group Purchasing Organization to enhance patient access to ZELSUVMI, which began formulary inclusion updates on December 1, 2025 [2] - The CEO of Pelthos, Scott Plesha, emphasized that this partnership with a national pharmacy benefit manager is a significant milestone for increasing commercial coverage and improving access for patients seeking at-home treatment [3] - The Chief Commercial Officer, Sai Rangarao, stated that the PBM partnership aligns with the company's commitment to reducing barriers for patients and enhancing access to ZELSUVMI [4] Product Information - ZELSUVMI is a topical nitric oxide-releasing gel indicated for the treatment of molluscum contagiosum in adults and pediatric patients aged one year and older, launched in July 2025 [3][6] - The product is designed for convenient at-home application and is effective for treating infections in sensitive areas of the body [3][6] - ZELSUVMI received a Novel Drug designation from the FDA in January 2024, marking it as the first and only prescription therapy approved for at-home use [1][6] Industry Context - Molluscum contagiosum is a highly contagious viral skin infection, particularly prevalent among children, with a significant portion of cases going untreated [5] - The condition can lead to discomfort and social stigma, with 30% of children experiencing lesions that persist beyond 18 months [5]

Core Viewpoint - Pelthos Therapeutics Inc. is actively engaging with investors and the healthcare community through participation in the Piper Sandler 37th Annual Healthcare Conference, highlighting its commitment to addressing unmet patient needs with innovative therapeutic products [1][2]. Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on commercializing innovative, safe, and effective therapeutic products for patients facing unmet treatment burdens [3]. - The company's lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, received approval from the U.S. Food and Drug Administration in 2024 for the treatment of molluscum contagiosum [3]. Event Participation - CEO Scott Plesha will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 9:30 a.m. Eastern Time [1]. - Institutional investors can schedule one-on-one meetings with Mr. Plesha through their Piper Sandler representatives [2]. - A live webcast of the fireside chat will be available on the company's website approximately two hours after the event [2].

Core Viewpoint - Pelthos Therapeutics has acquired U.S. commercialization rights to Xepi® (ozenoxacin) Cream, a topical treatment for impetigo, marking a significant step in addressing unmet patient needs in pediatric dermatology [1][4][8] Acquisition Details - Pelthos will pay a total of $4.2 million upfront for the acquisition, consisting of $3.0 million to Biofrontera and $1.2 million to Ferrer, with additional payments tied to commercial availability and sales milestones [3][4] - The acquisition is expected to enhance Pelthos's portfolio, which is anchored by its existing product ZELSUVMI™ [8][10] Market Context - Impetigo affects approximately 3 million people annually in the U.S., predominantly children aged 2 to 5, highlighting a significant market opportunity for Xepi [5][8] - The rise of bacterial resistance to common topical antibiotics has created a pressing need for effective alternatives, positioning Xepi as a critical treatment option [6][8] Financing Details - Pelthos has secured $18 million through private convertible notes financing, which will support the acquisition and re-launch of Xepi, as well as the commercialization of ZELSUVMI [2][7][9] - The notes will bear an interest rate of 8.5% per annum and are convertible at an initial price of $34.442 [7][10] Strategic Implications - The acquisition and financing are seen as strategic moves to bolster Pelthos's commercial growth and leverage its existing infrastructure to promote multiple innovative brands [4][10] - The company plans to re-launch Xepi in late 2026, aiming to provide a novel treatment option in the pediatric dermatology space [4][8]

Core Viewpoint - Pelthos Therapeutics has acquired U.S. commercialization rights to Xepi® (ozenoxacin) Cream, a topical treatment for impetigo, marking a significant step in addressing unmet patient needs in pediatric dermatology [1][4][8] Acquisition Details - Pelthos will pay a total of $4.2 million upfront for the acquisition, consisting of $3.0 million to Biofrontera and $1.2 million to Ferrer, with additional payments tied to commercial availability and sales milestones [3] - The acquisition is expected to enhance Pelthos's portfolio, which is anchored by its existing product ZELSUVMI™ [8] Market Context - Impetigo affects approximately 3 million people annually in the U.S., predominantly children aged 2 to 5, highlighting a significant market opportunity for Xepi [5][8] - The need for effective alternatives to traditional treatments is underscored by rising bacterial resistance, particularly to commonly used topical antibiotics [6] Financing Details - Pelthos has secured $18 million through private convertible notes financing, which will support the acquisition and re-launch of Xepi, as well as the commercialization of ZELSUVMI [2][7][10] - The notes will bear an interest rate of 8.5% per annum and are convertible at an initial price of $34.442 [7] Strategic Implications - The acquisition of Xepi is seen as a strategic move to leverage Pelthos's existing commercial infrastructure and expand its product offerings in the pediatric and dermatology markets [4][10] - The company aims to re-launch Xepi in late 2026, positioning it as a critical treatment option amid growing concerns over antibiotic resistance [4][8]

Core Viewpoint - Pelthos Therapeutics Inc. will hold a conference call on November 13, 2025, to discuss its third-quarter financial results for the period ending September 30, 2025 [1][2] Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on commercializing innovative therapeutic products for unmet patient needs [2] - The company's lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, was approved by the U.S. Food and Drug Administration in 2024 for the treatment of molluscum contagiosum [2]

Core Insights - Pelthos Therapeutics Inc. has launched the "Moms Against Molluscum" movement to support families dealing with molluscum contagiosum, a highly contagious skin infection affecting millions, particularly children [1][8]. Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on developing innovative therapeutic products for unmet patient needs, with its lead product being ZELSUVMI™ (berdazimer) topical gel, approved for treating molluscum contagiosum [13]. Product Information - ZELSUVMI is a topical nitric oxide-releasing gel, effective for treating molluscum in patients aged one year and older, and is the first FDA-approved at-home treatment for this condition [4][10]. - The product was launched in July 2025 and is designed for convenient application, allowing treatment at home or on-the-go [4][10]. Market Context - Molluscum contagiosum affects an estimated 16.7 million people in the U.S., with around 6 million new cases annually, primarily among children [2][7]. - Approximately 41% of children with molluscum will transmit the infection to others in their household, highlighting the need for effective treatment options [2]. Community Engagement - The "Moms Against Molluscum" movement aims to empower families to share their experiences and educate them about new treatment options, fostering a supportive community [5][6]. - Pelthos is actively promoting this initiative through social media to raise awareness and encourage discussions about molluscum contagiosum [6].

Core Viewpoint - Pelthos Therapeutics Inc. is actively participating in the Wells Fargo Healthcare Conference, showcasing its commitment to addressing unmet patient needs through innovative therapeutic products [1][2]. Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on commercializing safe and effective therapeutic products for patients with unmet treatment burdens [3]. - The company's lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, received FDA approval in 2024 for the treatment of molluscum contagiosum [3]. Event Details - The management presentation at the Wells Fargo Healthcare Conference is scheduled for September 3, 2025, at 1:30 p.m. E.T. [1]. - A webcast of the presentation will be available on Pelthos' website, with archived replays accessible for 90 days post-event [2].

Core Insights - Pelthos Therapeutics Inc. has launched ZELSUVMI™ (berdazimer) topical gel, a novel treatment for molluscum contagiosum, which is the first prescription therapy approved for at-home use by patients and caregivers [1][7][10] - The product received Novel Drug designation from the U.S. FDA in January 2024 and is aimed at addressing a significant unmet medical need for patients suffering from this highly contagious viral skin condition [1][7][10] Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on commercializing innovative therapeutic products to meet high unmet patient needs [10] - The company’s lead product, ZELSUVMI, was approved by the U.S. FDA in 2024 and is designed to be safe and effective for treating molluscum contagiosum [10] Product Details - ZELSUVMI is a once-daily topical gel that releases nitric oxide, indicated for the treatment of molluscum contagiosum in patients aged one year and older [7][10] - The product was validated through a Phase 3 clinical trial involving 891 patients, showing nearly 33% complete clearance of lesions at week twelve compared to 19.7% in the control group [2][7] Market Need - Molluscum contagiosum affects an estimated 16.7 million people in the U.S., with up to 6 million new cases annually, primarily among children [4][5] - Many parents delay treatment due to the inconvenience of current procedural options, highlighting the need for an effective at-home treatment like ZELSUVMI [3][4] Commercial Strategy - Pelthos has initiated the ZelsuvmiGo patient support program to facilitate patient onboarding and provide resources for caregivers [3] - The company has hired 50 sales territory managers to promote ZELSUVMI to physicians treating high volumes of molluscum patients and has implemented extensive digital outreach efforts [3][5]